Dr Scarfo speaks with ecancer at EHA 23 about a multicentre international study which finds 50% of CLL patients who have received Brutons tyrosine kinase inhibitor ibrutinib in the course of their CLL treatment who relapse harbour mutations in BTK and associated PLCG2 genes.

She outlines the recruitment procedure and patient cohort, and implications of these findings for screening and treatment guidance.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.